retatrutide type 2 diabetes phase 2 results 2024 Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, 3 π READY TO LEVEL UP
Description
Both drugs may cause mild but manageable GI side effects , such as nausea, vomiting, and diarrhea
Neuropharmacology (2015) 89:17584

Beware of prices significantly below $199 monthly or above $350 monthly, as these may indicate quality concerns or excessive markup respectively

They're everywhere
